ACTRN12613001148763
Not yet recruiting
Phase 3
Comparison of Fluticasone and Budesonide Intranasal Corticosteroid in Terms of Taste, Sensation, Delivery and Adherence in Children Aged 6-14 Years with allergic rhinitis (Hayfever)
Mater Health Services0 sites110 target enrollmentOctober 15, 2013
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Allergic rhinitis
- Sponsor
- Mater Health Services
- Enrollment
- 110
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Children aged 6\-14 years.
- •2\.Symptoms of perennial allergic rhinitis which following clinician assessment is felt to warrant treatment (persistent or moderate to severe intermittent allergic rhinitis).
- •3\. Not currently using a nasal corticosteroid.
Exclusion Criteria
- •1\. Hypersensitivity or intolerance to steroids.
- •2\. Currently using or having used an inhaled corticosteroid in the previous month.
- •3\. Currently taking Montelukast.
- •4\. No sense of smell.
- •5\. Receiving immunotherapy.
- •6\. Epistaxis in the previous week.
- •7\. Evidence of broken skin involving the nasal mucosa.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A clinical trial to comparatively evaluate budesonide versus fluticasone nebulisation for prevention of post operative sore throatCTRI/2024/08/072501Dayanand Medical College and Hospital
Recruiting
Phase 2
Comparison the effectiveness of budesonide and fluticasone propionate on asthma controlIRCT20100104002976N4Zanjan University of Medical Sciences50
Completed
Not Applicable
Comparison of Nasal Steroids After FESS in CRSwNPSinusitisNasal PolypsNCT02194062Yale University32
Completed
Not Applicable
Ciclesonide comparison with fluticasone in mild persistent asthmaAsthma.Asthma, unspecifiedIRCT201201028597N1Massih Daneshvari hospital356
Active, not recruiting
Phase 1
A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal allergiesEUCTR2015-004885-27-Outside-EU/EEAGlaxoSmithKline Research & Development Ltd936